F520
Asset
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 177
- Trials
- 1
- Developer
Indications
1Cancer of unknown primary site
Phase 2, Recruiting, NCT07761429, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials177
- Evidence for its targets1
- Competitors6
- Signals12
Every asset’s record: target, stage, trials and the evidence behind it.